Our Management Team

Josh Ginsberg, President and CEO

Josh Ginsberg is a seasoned entrepreneur and strategic advisor with over 14 years of experience in the cannabis industry. He has extensive experience in all facets of the cannabis supply chain, specializing in building vertically integrated retail, cultivation, and manufacturing businesses. He has a demonstrated track record of building cannabis businesses with accelerated and strategic growth trajectories.

Josh has founded and built several cannabis companies across North America. Notably, he co-founded Native Roots in 2009 and facilitated the business’s expansion and growth across the state of Colorado. It is currently one of the largest legal cannabis production and distribution companies in the world with over $100 million annual revenue, 21 retail locations, and more than 650 employees. He was also co-founder of Coastal Holding Company, a California cannabis organization, which obtained 10 licenses throughout the state and generated $100MM in sales during its three years of operations before a successful $65MM divesture to a publicly traded company.

Josh has guided many businesses to the successful acquisition of merit-based licenses in the United States. His team in Ohio, Can-Med Therapeutics, obtained four merit-based medical retail-dispensing licenses, one large-scale cultivation license, and one manufacturing license. In Missouri, Ginsberg was the co-founder of US Canna Old-Route 66 Wellness, which was awarded cultivation, manufacturing, and three retail licenses through a merit-based state application process. His team in Illinois won five Micro Cultivation licenses and two Retail Dispensary licenses and will be opening the first "Cookies" stores in the state. In New Jersey, he and his team obtained one of 37 cultivation licenses. Ginsberg also has a rapidly expanding retail dispensary brand in Canada, which currently holds four licenses and more in the pipeline. Josh also has extensive expertise in the CBD industry and is co-founder and Strategic Advisor of YZ CBD, LLC, a hemp-derived CBD Extraction Company with a global expansion and B-to-B distribution blueprint.

John Muse, Texas Board of Director

John Muse is a Texas-based businessman, investor, and philanthropist. A Texas native, he has spent the past 33 years as an investor and strategic advisor to a variety of companies across the consumer products, energy, and media sectors. Muse is a veteran and passionate about providing alternative forms of medicinal treatment for veterans suffering from PTSD.

In 1989, Muse co-founded Hicks Muse & Co., a private equity fund. Over the next 10 years, he raised six funds totaling over $6 billion, concentrating on investments in the consumer products, energy, and media sectors. Mr. Muse served as a board member on a number of portfolio companies and served on the firm’s investment committee. In 1998, he successfully extended the firm’s investment activities into Europe and raised two funds totaling over $3 billion. Upon Mr. Muse’s return to the US in 2005, he continued to serve on the investment committee of the European operation and as a board of director for a number of the European portfolio companies. In 2007, HM Capital Partners (the successor to Hicks, Muse) raised its eighth fund – the Sector Performance Fund. In 2011, he directed the rebranding of the firm to Kainos Capital, focusing exclusively on the consumer branded products sector.

Muse manages his family office, Muse Family Enterprises (“MFE”) out of Dallas. Its holdings include a majority stake in Lucchese, Inc., the premier manufacturer of western boots, and Free Flow Wines, the leading supplier of alternative packaging to the wine industry through kegs and cans. He is Chairman of both Lucchese and Free Flow. His family office manages intergenerational wealth for his family, his grown children, and for his family’s Muse Family Foundation, whose principal initiatives are to address opportunity gaps in education, affordable housing, and healthcare. Mr. Muse is a graduate of the United States Air Force Academy and received his MBA from the University of California, Los Angeles.

Julian Michalowski, Chief Operating Officer

Julian Michalowski is an experienced cannabis and real estate investor and strategic advisor. He has a successful history of accelerating the growth and profitability of startups and has generated more than $600 million in business growth throughout his career working with complex startups and commercial real estate developments. Julian specializes in identifying initial corporate risks, raising capital, building teams, and guiding businesses to successful Mergers & Acquisitions. Julian also has extensive expertise in forming and validating deal structure and facilitating negotiations during M&A, primarily in the Cannabis and Real Estate Development spaces. Julian holds 31 cannabis licenses in the United States.

Notably, Julian was the Founder/CEO/Chairman of the Board of Coastal Holding Company, a California cannabis organization. Julian was responsible for overall growth strategy, which led to obtaining 10 licenses and an exit in four years. Under Julian’s leadership, Coastal generated $100MM in sales during its three years of operations. He raised $16MM in equity funding and eventually negotiated and directed the successful $65MM divesture to a publicly traded company.

Additionally, Julian was founder and chairman of the board of Hulsa Wellness, a MLM CBD product line, and was responsible for the BOD, C Suite Team. He led the teams in raising capital and negotiating successful exits. Julian is Founder, Principal, and Board member of Omega Real Estate and Investments, a brokerage based in Santa Barbara, CA, that handles $30 to $40 million in real estate transactions each year. Julian is also the Founder, Principal, and Board member of West Bluff Capital, Inc., a fund based in Santa Barbara focused on real estate and venture capital investments.

Rob Roscow, Chief Science Officer

Robert’s substantial expertise includes genetic engineering, molecular biology, bioinformatics, plant breeding and tissue culture, photomicroscopy, unicellular microinjection, fish husbandry and breeding colony maintenance and transfection.

Following academic work studying the genetic dynamics of cellular patterning, Robert applied his advanced knowledge to cannabis plant enhancement. He joined ebbu in 2015, where he assisted in the development, commercialization and sale of intellectual property. There, Robert single-handedly invented IP related to the commercial optimization of Cannabis sativa, industrial hemp and hops, resulting in three pending US patents; including the first documented use of CRISPR based methodologies in C. sativa. He also coded and conceptualized automated statistical analysis behind human trials of cannabis formulations.

In 2019 Rob oversaw the design, build and staffing of a plant analytical chemistry laboratory in Ontario, Canada, for Canopy Growth Corporation where he was Lead Director of Genetic Research. He also participated in the Colorado Hemp Advancement & Management Plan Initiative Cannabis Industry as an industry stakeholder in 2019.

Now Robert brings his diverse background in biology, biotechnology, policy and intellectual property to innovation in the incredibly exciting mycology space as the CSO of Mydecine Innovations Group.

Colonel (Retd) Rakesh Jetly, OMM, CD, MD, FRCPC, Medical Director

TexaRx’s Medical Director, Dr. Rakesh Jetly, is the former Chief of Psychiatry for the Canadian Armed Forces and an internationally recognized expert on military and veteran mental health,

suicide prevention, and post-traumatic stress disorder. He began his career as a general duty medical officer and flight surgeon and was deployed to Rwanda and the Middle East. Inspired by

these experiences and motivated to address the psychological burden of deployments, he completed postgraduate training in psychiatry at the University of Toronto with a focus on psychological trauma. Dr. Jetly has been instrumental in the modernization and overhaul of the Canadian military mental health system since 2000. He was deployed twice to Kandahar, Afghanistan, where he was the lead of the mental health team at the Role 3 Hospital. Over the last 10 years of his career, Dr. Jetly has served as the senior clinician overseeing the clinical care provided by over 400 mental health professionals within the Canadian Armed Forces, as well being the advisor to the Canadian Surgeon General. Colonel Jetly’s leadership has extended beyond Canada, and he has worked closely with NATO to chair expert panels in areas such as the “Morality and Mental Health,” “Leveraging Technology in Mental Health,” and “Precision Medicine.” He also is currently a consultant with the United Nations as this organization works to establish a mental health strategy for peacekeepers. Despite a busy military career, Dr. Jetly has maintained academic positions at both Dalhousie University and the University of Ottawa. He has taught postgraduate trainees in psychiatry and supervises PhD students as well as being a senior scientist In the Institutional for Mental Health (IMHR) in Ottawa. His research interests have included dozens of studies ranging from understanding the biological underpinnings of mental illness to precision/personalized medicine.

Dr. Jetly has published over 100 peer-reviewed articles and book chapters on topics ranging from suicide prevention, post-traumatic stress disorder, and moral injury. He is the lead author of the

“The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD,” one of the only Randomized Controlled Trials examining the use of cannabinoids to treat PTSD. Dr. Jetly has also co-authored the following publications: “A Review of the Neurobiological

Basis of Trauma-Related Dissociation and Its Relation to Cannabinoid- and Opioid-Mediated Stress Response: a Transdiagnostic, Translational Approach,” and “A Review of the Neurobiological Basis of Trauma-Related Dissociation and Its Relation to Cannabinoid- and

Opioid-Mediated Stress Response: a Transdiagnostic, Translational Approach.” He is also co- author of “Cannabis use among Canadian Armed Forces members and Veterans: discussion from

a 2017 CIMVHR Forum working group.”

Dr. Jetly presents nationally and internationally on such topics as post-traumatic stress disorder and operational psychiatry and has been a keynote speaker at conferences throughout North

America, Europe, and Australia. In 2015, he was appointed the inaugural “Canadian Forces Brigadier Jonathan C Meakins Chair in “Military Mental Health.” He was also named a Fellow of the American Psychiatric Association and The Canadian Institute for Military and Veterans Health Research (CIMVHR).

Eduard Linetskiy, Chief Compliance Officer

Eduard Linetskiy is a strategic advisor with over six years of experience in all facets of cannabis regulatory compliance, including auditing, operational support, and surveillance.

Eduard served as Vice-President of Compliance for MedMen, where he ensured that all national retail, cultivation, manufacturing, distribution, and vertical assets remained in compliance with applicable state and local cannabis regulations. In this role, he became well versed in the day-to-day operations and best practices of cannabis operations across all license types and many regulatory frameworks. During his tenure, he created and implemented a nationwide compliance, audit, and monitoring program for assets in Arizona, California, Florida, Illinois, Massachusetts, Nevada, and New York. . During his time as Vice President he ensured that there were no material violations across any state or license.

Prior to joining MedMen, Eduard was the Compliance Director for Los Angeles-based global investment bank Houlihan Lokey, which is a world-leading advisor in mergers, acquisitions, transactions and restructuring. He also worked at MetLife, one of the largest global insurance providers and was a financial and operational examiner for the New York Stock Exchange. Eduard holds an MBA from NYU Stern School of Business and until joining the cannabis space, maintained several financial services licenses. He brings class-leading operational and compliance expertise and unprecedented skills to the fast changing and fast-growing cannabis industry.

Patricia Haley, Chief Security Officer

Patricia Haley will serve as TexaRx’s Director of Security. Haley is a United States Marine Corps veteran, a former Special Agent with the FBI focused on health care fraud and public corruption investigations, and a government defense security contractor for the Pentagon Force Protection Agency and the Department of Homeland Security. She has also served as a council woman and rural police chief in West Virginia. She is the principal consultant entrepreneur of PWG, minority woman owned (“WO”) certified Service-Disabled Veteran (“SDVOSB”) owned security consulting firm. She holds national certifications in defensive tactics, firearms, and active shooter preparedness. She is a subject matter expert in the field of medical cannabis security. Ms. Haley has established and implemented security programs for licensed medical cannabis facilities in Ohio, Pennsylvania, Utah, and West Virginia. She is also a security advisor for a recreational cannabis facility in Massachusetts. Ms. Haley serves on the ASTM International Cannabis Security and Transportation chairperson, which is responsible to over 150 international voting member experts in cannabis security standardization. The ASTM International D37 Cannabis Committee develops international standards and certifications for hemp and cannabis.

Dr. Susan Audino, Lab Director

Dr. Susan Audino, PhD is a chemist/chemometrician and independent consultant to chemical and biological laboratories. On behalf of Accreditation Bodies, she assesses laboratories to and is an instructor for multiple ISO/IEC standards including ISO 17025. She is highly visible in the cannabis industry as a leader for the development of official/consensus test methods and quality in science and is a member of expert review panels. She also serves as a scientific advisor to multiple cannabis testing laboratories, private and non-profit cannabis organizations including Emerald Scientific and The Cannabis Science and Technology journal, and state regulatory bodies. Dr. Audino has chaired the AOAC cannabis advisory panel and analytical cannabis working groups was a member of the NCIA Guide for Laboratory Testing, is a faculty member of Teachable Medicine, Board Member of Hood College, Board Member of The Center for Research on Environmental Medicine and has been an invited speaker at many domestic and international scientific conferences. Dr. Audino is principal at S.A. Audino & Associates, LLC, principal at RWD, LLC, principal at Executive Quality Management, LLC, and Vice President & Sr. Science Officer at RCU Laboratories.

Emily Fata, Director of Application

Emily has worked as a financial analyst, writer, and consultant within the cannabis industry since 2013. She is the founder of Diagon, a boutique consulting firm focused on creating license applications, financial models, valuations, and market analysis studies for cannabis entrepreneurs and investors.

Emily has worked with several companies in Colorado, Washington, Nevada, Illinois, Oregon, Maryland, Hawaii, California, Florida, New Mexico, Massachusetts, Michigan, Vermont, Rhode Island, Georgia, Colombia, Germany, and Malta raise capital and apply successfully for government-issued cannabis cultivation, retail, and manufacturing licenses. She has also collaborated with several legal and consulting firms, such as Denver Relief Consulting and Vicente Sederberg, advising entrepreneurs on financing, licensing, and starting a cannabis company.

Emily also works as a strategic advisor to investors and business owners seeking to expand operations domestically and globally. An industry expert and analyst, she has published several articles in Marijuana Investor News and New Cannabis Ventures and is the creator of the Cannabis Science Today podcast. Emily began her career as an analyst at Fundamental Advisors, a private equity firm in New York City specializing in distressed debt and municipal bonds. .

Byron Campbell, Director of Government Affairs

Byron graduated from the University of North Texas in 2005 with a BA in Political Science and as a varsity letterman for the football team. After completing an internship in Congressman Pete Sessions office in Washington DC, Byron was hired as a Legislative Assistant (LA) on the Education and Workforce Committee in the US House of Representatives, serving then Chairman John Boehner. Byron also served as an assistant to the committee’s budget professional staff throughout the budget process. In the fall of 2006, Byron was asked to join Congressman Pete Sessions campaign as his Field Director. In coordination with the Congressman himself, Byron and the Campaign Manager directed and organized all activities in 188 precincts within the 32nd Congressional District. His result exceeded the initial vote goal by over 5000 votes district wide.

Shortly after leaving this successful campaign, Byron was hired as Senator Kay Bailey Hutchison’s Regional Director for North Texas. Having already worked in Washington, and developed key contacts in the DFW region through his campaign efforts, Byron made a seamless transition to the Senate. While many of his duties centered around travelling with the Senator and planning her speaking events within the region, Byron also directed outreach initiatives for 54 diverse counties in Northeast Texas. While traveling throughout North Texas, he met with and established close relationships with County Judges, Mayors, City Council and other elected officials along with local business and community leaders.

Since late 2011, Byron has served as Senior Partner in the business and legislative consulting firm based in Dallas. They serve a broad spectrum of clients such as telecommunications, local municipalities, transportation, information technology, and private law enforcement at the federal, state and local levels. Byron also served as Chairman of the national board of directors for the University of North Texas Alumni Association from 2014-2016.

Our Scientific & medical advisory board

Dr. Carl Andrew Castro, Ph.D.

Dr. Carl Castro is currently Professor and Director of the Military and Veteran Programs at the Suzanne Dworak-Peck School of Social Work at the University of Southern California. Before joining the University of Southern California, Professor Castro served in the U.S. Army for over

30 years, retiring at the rank of colonel. Dr. Castro participated in the Bosnia and Herzegovina and Kosovo Campaigns, Operation Northern Watch, and the Iraq War.

Dr. Castro has chaired numerous NATO and international research groups and he is currently Co-Chair of a NATO group exploring Military and Veteran Radicalization. His current research efforts are broad and include: (a) the exploration of the military culture that leads to acceptance and integration of diverse groups; (b) understanding and ameliorating the effects of military trauma and stress, especially combat and deployment, on service members and their family; (c)

the prevention of suicides and violence such as sexual assault and bullying; and (d) evaluating the process of transitioning into the military and transitioning from military service back to civilian life.

He has authored more than 150 scientific articles and reports in numerous research areas, including the “Unintended Consequences of Changing the Definition of Posttraumatic Stress Disorder in DSM-5 Critique and Call for Action,” “PTSD and Physical Health Symptoms

Among Veterans: Association with Child and Relationship Functioning,” and “PTSD symptoms, suicidality and non-suicidal risk to life behavior in a mixed sample of pre- and post-9/11 veterans.” Dr. Castro’s distinguished military career coupled with his industry-leading research on military mental health will contribute to advance veteran-based clinical trials for the treatment of PTSD.

Dr. GARY H. WYNN, MD, COL (Retd), MC, USA

Dr. Gary Wynn is a consultant psychiatrist and senior medical officer for Capital and Coast District Health Board (CCDHB) in Wellington, New Zealand. He is a Professor of Psychiatry and Neuroscience at the Uniformed Services University of the Health Sciences and a Senior

Scientist at the Center for the Study of Traumatic Stress. He was most recently the Assistant Chair of the Department of Psychiatry at the Uniformed Services University of the Health Sciences located in Bethesda, Maryland, USA. He is also a Distinguished Fellow of the American Psychiatric Association and on the editorial board of the Journal of Neuroscience Research. Dr. Wynn received his education at the United States Military Academy at West Point and Uniformed Services University of the Health Sciences. He completed a dual residency in psychiatry and internal medicine at the Walter Reed Army Medical Center in Washington, D.C. During his military career Dr. Wynn has served as a Division Psychiatrist (2nd Infantry Division, Korea), Assistant Chief of Inpatient Psychiatry Services (Walter Reed), and as a Research Psychiatrist (Walter Reed Army Institute of Research)

prior to transitioning to the Uniformed Services University of the Health Sciences.

Dr. Wynn has served as a frequent member of DoD level committees and working groups on the topics of trauma, PTSD, and suicide. Dr. Wynn has served as a member of various boards and committees for the US Department of Veterans Affairs and the National Institute of Mental Health as well as being US Representative and Chair for NATO Human Factors in Medicine panels on Leveraging Technology in Military Mental Health and Precision Medicine in Human Performance and Mental Health. He is a member of the Order of Military Medical Merit and recipient of the US Army Medical Department “A” Proficiency Designator, the Rundell Award, the Artiss Award, and three Meritorious Service Medals. From 2015 to 2019, Dr. Wynn served as the primary investigator of a research project funded by the Military Operational Medicine Research Program examining the Evaluation of the Safety and Pharmacokinetics of the FAAH Inhibitor URB597.

Dr. Wynn is a Past President of the Society of Uniformed Services Psychiatrists (District Branch of the American Psychiatric Association) and has over 100 publications including two books, Complementary and Alternative Medicine for PTSD, published in 2016, and Clinical Manual for the Management of PTSD published in 2010. He is the co-author of the “The Role of Endocannabinoid Function in Posttraumatic Stress Disorder: Modulating the Risk Phenotype and Rendering Effects of Trauma,” which can be found in Chapter 11 of textbook: Cannabinoids in

Neurologic and Mental Disease, as well as “Effects of fatty acid amide hydrolase inhibitor URB597 in a rat model of trauma-induced long-term anxiety,” which was published in Psychopharmacology in 2018.

Professor dr Col ret’d HGJM (Eric)Vermetten, MD, PhD

Professor dr Col ret’d HGJM (Eric) Vermetten, MD, PhD, is a psychiatrist and a full professor at

Leiden University Medical Center in the Netherlands. He has been working as Strategic Advisor (COL) of Research at the Military Mental Health Service with the Dutch Ministry of Defense and ARQ National Psychotrauma Center. He also has an Adjunct Professorship at the Department Psychiatry of New York UMC. He has trained in the Netherlands as well as in the USA in psychiatry and neuroscience (Stanford, Yale and Emory University).

Professor Vermetten has clinical and research experience focusing on the medical, biological, and psychiatric aspects of complex psychotrauma in military as well as civilian populations. He is an internationally recognized expert in the field of stress, trauma, PTSD, and neuroscience. He is interested in the history of war and has special focus on combining biological-based interventions in psychotraumatology with novel technology such as VR, and novel drug developments, e.g. medical cannabis, and psychedelics. He is the Primary Investigator of a 10-

year longitudinal cohort study of prospective research in military operations, PRISMO. Professor Vermetten has lectured on the topic of PTSD, resilience, militaryand veterans’ issues as well as

novel approaches to therapy across the globe. He is currently consulting for United Nations on Mental Health in Peacekeeping. He has published over 300 articles and book chapters on topics ranging from large longitudinal studies following soldiers’ deployments to innovative

approaches to treatment. A sampling of his publications include:

• “Reviewing the potential of psychedelics for the treatment of PTSD.” International Journal of Neuropsychopharmacology, 23(6), 385-400. (Published in 2020.)

• “Toward staging differentiation for posttraumatic stress disorder treatment.” Acta Psychiatrica Scandinavica, 147(1), 65-80. (Published in 2023.)

• “Experiences with medical cannabis in the treatment of veterans with PTSD: Results from a focus group discussion.” European Neuropsychopharmacology, 36, 244-254. (Published in

2020.)

• “A review of the neurobiological basis of trauma-related dissociation and its relation to cannabinoid-and opioid-mediated stress response: A transdiagnostic, translational approach.” Current Psychiatry Reports, 20, 1-14. (Published in 2018).

• “Medication for sleep problems in posttraumatic stress disorder. Sleep and combat-related post traumatic stress disorder,” 325-348. (Published in 2018)

Dr. Alexander (Sandy) McFarlane

Dr. Alexander McFarlane is an international expert in the field of the impact of disasters and posttraumatic stress disorder (PTSD). He served as a Professor of Psychiatry in the School of

Medicine at the University of Adelaide for 32 years and was the Director of the Centre for Traumatic Stress Studies at the University of Adelaide from 2011 to 2019.

Dr. McFarlane’s research has focused on the epidemiology and longitudinal course of PTSD as well as the neuroimaging of the cognitive deficits in this disorder. He has published over 250 articles and chapters in various refereed journals and has co-edited three books. In the medico-legal arena, he has long standing experience, including writing a report for the United Nations about the Compensation Commission for the Iraqi occupation of Kuwait and has also been engaged by the Ministry of Defense in the United Kingdom in the matters relating to

the Falkland Island, Gulf War and Northern Ireland Veterans. Professor McFarlane has acted as special advisor to the Department of Veteran's Affairs, including the Scientific Advisory committee examining the health and psychological status of Gulf War Veterans. A Past President of both the International Society for Traumatic Stress Studies and the Australasian Society for Traumatic Stress Studies, and a recipient of the Robert Laufer Award for outstanding scientific

achievement in the field of traumatic stress.

In 2008, he was awarded the Organon Senior Research Award of the RANZCP for the most outstanding contribution to psychiatric research in the last five years. He was also recipient of the Founders; Medal of the Australasian Society for Psychiatric Research awarded to individuals who have made a significant contribution to psychiatric research over the course of their career. While serving as the Director of the Centre for Traumatic Stress Studies, Professor McFarlane’s

served as the Chief Investigator of the Middle East Area of Operations Deployment Health Surveillance Program. This $11 million Defense funded project assessed the physical and psychological health of all of the 25,000 Australian Defense Force members who have been

deployed to the Iraq and Afghanistan conflicts. One component of this project used a prospective methodology to study troops prior to and after deployment. He was also the Principal

Investigator of the 2010 ADF Mental Health and Wellbeing Study and the Transition and Wellbeing Study, investigating all personnel who have left the ADF since 2010. He held an NHMRC Program Grant from 2015-2019, worth $12 million dollars, investigating the aetiology, course, and treatment of posttraumatic psychopathology with Professors Bryant, Silove, Mahli, Felmingham and Creamer. In 2011, Professor McFarlane received the Officer of the Order of Australia Award in the

Australia Day Honors List.

The award recognizes outstanding contributions to medical research in the field of psychiatry, particularly posttraumatic stress disorders, to veterans’ mental health management, and as an author. In 2012, he was awarded the Lifetime Achievement Award from the International Society of Traumatic Stress Studies. This award recognizes years of service and leadership in the field of traumatic stress. In 2016, Professor McFarlane became one of the three Australians to be awarded an Honorary Fellowship of the American College of Psychiatry in recognition of his contributions to the field of traumatic stress. Professor McFarlane is the author of hundreds of published papers on PTSD, including the “Current challenges about the structure of treatment services for Military and Veterans Personnel: A potential strategy for knowledge informed policy decisions and service development to lessen the risk of suicide,” as well as “Toward staging differentiation for posttraumatic stress disorder treatment.” These publications are featured in the appendix. He has

also co-published the following prominent research investigations on PTSD:

“Post-traumatic stress disorder,” Nature Reviews Disease Primers, 2015;1:1-22.

“Trajectory of posttraumatic stress following traumatic injury: a 6-year follow up,” British

Journal of Psychiatry, 2015;206(5):417-423.

“The Need to Take a Staging Approach to the Biological Mechanisms of PTSD and its

Treatment,” Current Psychiatry Reports, 2017;19(2):1-9).

“The ambivalence about accepting the prevalence somatic symptoms in PTSD: Is PTSD a

somatic disorder?” Journal of Psychiatric Research. 2021 Nov 1;143:388-94.

“Treatment augmentation for posttraumatic stress disorder: A systematic review.” Clinical

Psychology: Science and Practice. 2020 Mar;27(1):e12310.

“Treatment Resistance in Post-traumatic Stress Disorder (PTSD).” In: Yong-Ku Kim, editor,

Treatment Resistance in Psychiatry, Springer Nature, Singapore Pte Ltd, 2019.

“The long-term costs of traumatic stress: Intertwined physical and psychological consequences,”

World Psychiatry, 2010;9(1):3-10.

“Mental health in the Australian Defence Force: 2010 ADF Mental Health and Wellbeing Study:

Full Report.” Canberra: Department of Defence. 2011.

“Unintended consequences of changing the definition of posttraumatic stress disorder in DSM-

5,” JAMA Psychiatry, 2016;73:750-752.

Lynnette Astrid Averill, Ph.D.

Dr. Lynnette Averill is an expert in the evaluation of neurocognitive symptoms and the clinicalassessment and treatment of PTSD, suicidality, and other trauma- and stress-related psychopathology. Dr. Averill is currently an Associate Professor of Psychiatry and Behavioral

Sciences and Clinical Research Psychologist at Baylor College of Medicine and the Clinical Research Psychologist at the US Department of Veterans Affairs. Her work focuses on pharmacoimaging trials evaluating rapid-acting glutamatergic-based drugs on reductions in suicidal ideation and cognitive function and the neural underpinnings (e.g., synaptic connectivity) of these behavioral changes. She has extensive experience in translational clinical

neuroscience.

She has been devoted to the mental health of veterans and other survivors of trauma from a young age. Her father served as an enlisted infantryman with the U.S. Marine Corps in Vietnam, and like so many others, he struggled to cope with his experiences in theater, developing PTSD. He died by suicide when she was three years old after struggling with ineffective treatments and self-medication.

Dr. Averill previously served as an adjunct Assistant Professor at Yale School of Medicine She serves as a Founding Board Member for Source Research Foundation (a 501C3 focused on expanding psychedelic research) and the Associate Editor for the peer-reviewed journal Chronic

Stress and Clinical Director of the Emerge Research Program. She is a highly accomplished and well-rounded investigator with a record of achievement in scientific productivity, federal and private grant funding, and inter/national honors from prestigious academic and scientific

organizations (including a Fulbright Fellowship to Melbourne, Australia).

Dr. Averill’s research fills a critical niche in the field and has significant potential to maintain long-term priority funding. Her work has the translational potential to improve and save lives by informing our understanding of the causes and consequences of trauma-related psychopathology and suicidality, and through the investigation of novel rapid-acting interventions. Her clinical and research expertise is in the psychoneurobiology of suicidality and PTSD, and she has

successfully managed several pharmacoimaging clinical/mechanistic trials of rapid-acting antidepressants.

Dr. Averill has published widely on PTSD. Her papers include “Cannabis-assisted psychotherapy for complex dissociative posttraumatic stress disorder: A case report,” “Benchmarking Dialectical Behavior Therapy for Male Veterans with Posttraumatic Stress Disorder: A Pilot

Study,” and “The influence of measurement context on veterans' consistency in reporting posttraumatic stress disorder and post concussive symptoms.”